For the quarter ending 2025-09-30, MREO had -$7,009K decrease in cash & cash equivalents over the period. -$7,309K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,024 | -27,503 |
| Share-based compensation | 1,712 | 4,343 |
| Depreciation | 39 | 82 |
| Amortization of intangible assets | -183 | 224 |
| Amortization of operating lease right-of-use assets | 133 | 262 |
| Change in fair value of warrants | -196 | -315 |
| Interest income | 34 | - |
| Non-cash interest expense | 17 | 193 |
| Foreign currency transaction loss | 1,873 | -8,091 |
| Other income | 300 | - |
| Prepaid expenses and other current assets | 164 | 155 |
| Research and development incentives receivable | -1,661 | -208 |
| Accounts payable | -236 | -1,589 |
| Accrued expenses and other liabilities | -673 | 540 |
| Operating lease liabilities | -188 | -361 |
| Net cash used in operating activities | -7,309 | -15,980 |
| Payments for intangible assets | 0 | 300 |
| Purchase of property and equipment | 0 | 20 |
| Proceeds from out-licensing | 300 | - |
| Net cash used in investing activities | 300 | -320 |
| Proceeds from exercise of warrants | 0 | 487 |
| Proceeds from issuance of ordinary shares | 0 | 0 |
| Transaction costs on issuance of ordinary shares | 0 | 199 |
| Net cash provided by financing activities | 0 | 288 |
| (decrease)/increase in cash and cash equivalents | -7,009 | -16,012 |
| Cash and cash equivalents at beginning of period | 69,802 | - |
| Effect of exchange rate changes on cash | 1,917 | - |
| Cash and cash equivalents at end of period | 48,698 | - |
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)